156 related articles for article (PubMed ID: 12871552)
1. Reversible inhibitors of TAFIa can both promote and inhibit fibrinolysis.
Schneider M; Nesheim M
J Thromb Haemost; 2003 Jan; 1(1):147-54. PubMed ID: 12871552
[TBL] [Abstract][Full Text] [Related]
2. Two naturally occurring variants of TAFI (Thr-325 and Ile-325) differ substantially with respect to thermal stability and antifibrinolytic activity of the enzyme.
Schneider M; Boffa M; Stewart R; Rahman M; Koschinsky M; Nesheim M
J Biol Chem; 2002 Jan; 277(2):1021-30. PubMed ID: 11684677
[TBL] [Abstract][Full Text] [Related]
3. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent.
Bajzar L; Nesheim ME; Tracy PB
Blood; 1996 Sep; 88(6):2093-100. PubMed ID: 8822928
[TBL] [Abstract][Full Text] [Related]
4. Platelet factor 4 inhibits thrombomodulin-dependent activation of thrombin-activatable fibrinolysis inhibitor (TAFI) by thrombin.
Mosnier LO
J Biol Chem; 2011 Jan; 286(1):502-10. PubMed ID: 21041299
[TBL] [Abstract][Full Text] [Related]
5. Thrombin-activable fibrinolysis inhibitor zymogen does not play a significant role in the attenuation of fibrinolysis.
Foley JH; Kim P; Nesheim ME
J Biol Chem; 2008 Apr; 283(14):8863-7. PubMed ID: 18252711
[TBL] [Abstract][Full Text] [Related]
6. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability.
Walker JB; Bajzar L
J Biol Chem; 2004 Jul; 279(27):27896-904. PubMed ID: 15128744
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombin-activatable fibrinolysis inhibitor.
Ammollo CT; Semeraro F; Incampo F; Semeraro N; Colucci M
J Thromb Haemost; 2010 Apr; 8(4):790-8. PubMed ID: 20088944
[TBL] [Abstract][Full Text] [Related]
8. Plasma and recombinant thrombin-activable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties.
Boffa MB; Wang W; Bajzar L; Nesheim ME
J Biol Chem; 1998 Jan; 273(4):2127-35. PubMed ID: 9442053
[TBL] [Abstract][Full Text] [Related]
9. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
GuimarĂ£es AH; Rijken DC
Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
[TBL] [Abstract][Full Text] [Related]
10. Increased zymogen activity of thrombin-activatable fibrinolysis inhibitor prolongs clot lysis.
Mishra N; Buelens K; Theyskens S; Compernolle G; Gils A; Declerck PJ
J Thromb Haemost; 2012 Jun; 10(6):1091-9. PubMed ID: 22498006
[TBL] [Abstract][Full Text] [Related]
11. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
12. Generation of a stable activated thrombin activable fibrinolysis inhibitor variant.
Ceresa E; Van de Borne K; Peeters M; Lijnen HR; Declerck PJ; Gils A
J Biol Chem; 2006 Jun; 281(23):15878-83. PubMed ID: 16595693
[TBL] [Abstract][Full Text] [Related]
13. The impact of the endothelial protein C receptor on thrombin generation and clot lysis.
Pepler L; Wu C; Dwivedi DJ; Wu C; Kim PY; Liaw PC
Thromb Res; 2017 Apr; 152():30-37. PubMed ID: 28219843
[TBL] [Abstract][Full Text] [Related]
14. Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro.
Walker JB; Hughes B; James I; Haddock P; Kluft C; Bajzar L
J Biol Chem; 2003 Mar; 278(11):8913-21. PubMed ID: 12643276
[TBL] [Abstract][Full Text] [Related]
15. Generation and characterization of a highly stable form of activated thrombin-activable fibrinolysis inhibitor.
Marx PF; Havik SR; Marquart JA; Bouma BN; Meijers JC
J Biol Chem; 2004 Feb; 279(8):6620-8. PubMed ID: 14660622
[TBL] [Abstract][Full Text] [Related]
16. Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice.
Mao SS; Holahan MA; Bailey C; Wu G; Colussi D; Carroll SS; Cook JJ
Blood Coagul Fibrinolysis; 2005 Sep; 16(6):407-15. PubMed ID: 16093731
[TBL] [Abstract][Full Text] [Related]
17. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activable fibrinolysis inhibitor.
Wang W; Boffa MB; Bajzar L; Walker JB; Nesheim ME
J Biol Chem; 1998 Oct; 273(42):27176-81. PubMed ID: 9765237
[TBL] [Abstract][Full Text] [Related]
18. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin.
Colucci M; Pentimone A; Binetti BM; Cramarossa M; Piro D; Semeraro N
Thromb Haemost; 2002 Aug; 88(2):282-7. PubMed ID: 12195701
[TBL] [Abstract][Full Text] [Related]
19. Effect of warfarin treatment on thrombin activatable fibrinolysis inhibitor (TAFI) activation and TAFI-mediated inhibition of fibrinolysis.
Incampo F; Carrieri C; Galasso R; Scaraggi FA; Di Serio F; Woodhams B; Semeraro N; Colucci M
J Thromb Haemost; 2013 Feb; 11(2):315-24. PubMed ID: 23256818
[TBL] [Abstract][Full Text] [Related]
20. Lys 42/43/44 and Arg 12 of thrombin-activable fibrinolysis inhibitor comprise a thrombomodulin exosite essential for its antifibrinolytic potential.
Wu C; Stafford AR; Fredenburgh JC; Weitz JI; Gils A; Declerck PJ; Kim PY
Thromb Haemost; 2017 Jul; 117(8):1509-1517. PubMed ID: 28640323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]